RECRUITING

Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Talk to us

Conditions

Myelofibrosis; AnemiaAnemiaMyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraPrimary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisMyelodysplastic SyndromesMyeloproliferative NeoplasmMyeloproliferative Disorders

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.

Official Title

A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Quick Facts

Study Start:2022-06-06
Study Completion:2024-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05320198

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Disc Medicine Clinical Trials
CONTACT
(617) 674 9274
clinicaltrials@discmedicine.com

Principal Investigator

Will Savage, MD PhD
STUDY_DIRECTOR
Disc Medicine

Study Locations (Sites)

Mayo Clinic Jacksonville
Jacksonville, Florida, 32224
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Mayo Clinic Rochester
Rochester, Minnesota, 55905
United States
Washington University St.Louis
Saint Louis, Missouri, 63110
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10021
United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157
United States
Gabrail Cancer Center Research
Canton, Ohio, 44718
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States
Oregon Health and Science University
Portland, Oregon, 97239
United States
Sargon Research - Pennsylvania Cancer Specialists and Research Center
Gettysburg, Pennsylvania, 17325
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
MD Anderson
Houston, Texas, 77030
United States
University of Washington
Seattle, Washington, 98109
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Disc Medicine, Inc

  • Will Savage, MD PhD, STUDY_DIRECTOR, Disc Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-06
Study Completion Date2024-10

Study Record Updates

Study Start Date2022-06-06
Study Completion Date2024-10

Terms related to this study

Keywords Provided by Researchers

  • Myeloproliferative Neoplasm
  • Myeloproliferative Disorders

Additional Relevant MeSH Terms

  • Myelofibrosis; Anemia
  • Anemia
  • Myelofibrosis
  • Myelofibrosis Due to and Following Polycythemia Vera
  • Primary Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Myelodysplastic Syndromes